We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Phage Lytic Enzyme Specifically Attacks MRSA

By HospiMedica International staff writers
Posted on 01 Jul 2015
A novel bacteriophagic protein has been designed to attack methicillin-resistant Staphylococcus aureus (MRSA) microbes and dissolve them.

Developed by researchers at the German Center for Infection Research (DZIF; Braunschweig, Germany) and Hyglos (Bernried, Germany), HY-133 is a synthesized phage protein that was characterized and recombinantly expressed for the selective decolonization of pathogenic Staphylococcus aureus in the nasal passages. More...
Due to the highly specific action, the natural microflora is maintained, and HY-133 could therefore be used for the prophylactic treatment of nasal colonization, counteracting the spread of MRSA and thus preventing infections.

HY-133 was developed using proprietary phage-ligand technology, which exploit the principles of bacteriophage biology for diagnostic, antimicrobial, and research applications. The technology enables the production of advanced molecules for effective binding of bacteria, bacterial components, and lysis. Other applications of the molecules developed using the technology include food preservation, and decolonization of acne Propionibacterium germs and other bacterium, such as Clostridium difficile. HY 133 was presented at the BIO World Congress on Industrial Biotechnology, held during June 2015 in Montreal (Canada).

“We do like to describe it as a MRSA-killing protein, even if it sounds somewhat sensational,” said Wolfgang Mutter, PhD, MBA, of Hyglos. “In fact, all Staphylococcus aureus cells, whether resistant or not resistant, will be killed by this new active substance within a very short time. And this without the natural microflora in the nose being destroyed, nor does resistance develop.”

“A rapid detection and effective elimination of MRSA colonization in the nose prior to a hospital stay is a crucial step in combating these hospital germs,” added Prof. Karsten Becker, MD, of University Hospital Münster (Germany), a researcher at the DZIF. “The bacteria in the nose are increasingly resistant to the currently used antibiotic mupirocin and the duration of the decolonization and follow-up control is around one week. Under such circumstances, no effective MRSA prevention is possible for patients immediately in need of surgery.”

Bacteriophages recognize their host via proteins that bind to carbohydrate or protein structures on the surface of the bacteria. These phage proteins are very stable; some of them require heating at temperatures above 90 °C to destroy their three-dimensional structure. Phage proteins also have binding affinities comparable to monoclonal antibodies. Both properties provide durability in harsh environmental conditions, and allow bacteriophages to wait for the next opportunity to infect new host bacteria.

Related Links:

German Center for Infection Research
Hyglos



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.